Orexo has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialization of ZUBSOLV ((buprenorphine (as hydrochloride) and naloxone (as hydrochloride dihydrate)) sublingual tablet.
Licensed in Europe, ZUBSOLV is indicated for adults and adolescents over 15 years of age for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment, and who have agreed to be treated for addiction. ZUBSOLV offers an alternative treatment option for patients as it launches across 29 countries in Europe.
“I am excited about this new partnership with Accord and am looking forward to making ZUBSOLV available to patients in Europe suffering from opioid dependence. We have chosen Accord for their strong commitment to the addiction field and their successful track record in both generic and branded markets, which makes them ideally placed to make ZUBSOLV successful in the competitive European market,” says Nikolaj Sørensen, President and CEO of Orexo AB.
A common aim
This agreement brings together the experience of Orexo in the opioid addiction market alongside the commercial reach of Accord Healthcare, who are partnering together with a common aim to ensure that people have more access to treatment options. There are estimated to be 1.3 million high-risk opioid users in Europe, yet treatment rates are low with around 50 percent of people with opioid dependence receiving some form of substitution treatment and this can vary greatly between countries.
Under the terms of the agreement, Orexo will be responsible for product supply and Accord will take responsibility for the commercialisation of ZUBSOLV. Orexo will receive double-digit royalties on future net sales.
Photo of Nikolaj Sørensen, CEO, Orexo: Jenny Öhman/Nordic Life Science